The mutational burden, or the number of mutations present in a tumors DNA, is a good predictor of whether that cancer type will respond to a class of cancer immunotherapy drugs known as checkpoint inhibitors, a new study led by Johns Hopkins Kimmel Cancer Center researchers shows.
The finding, published in the Dec. 21 New England Journal of Medicine, could be used to guide future clinical trials for these drugs. Read more . . .